This sub-committees were time-limited, multi-disciplinary and utilised clinical expertise across the area. It is intended to fit with current good clinical practice across the Trust, and the evidence base. Responsibility for Formulary maintenance now reverts back to the on-going remit of the MOC. The Aim of the Formulary The aim of the Formulary is to advise clinicians on evidence based drug treatments, which are cost and clinically effective for the common mental disorders encountered in clinical practice.
At present, there are four categories of drugs in the HA Drug Formulary: General Drugs These are drugs with well-established indications and cost- effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics.
Special Drugs These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions.
Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs.
Self-financed Items SFIs with Safety Net These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense.
A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties. SFIs without Safety Net These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs e.
Patients who choose to use these drugs must purchase them at their own expense. Drug Formulary Committee DFC is tasked to review the current drug list in the HA Drug Formulary biennially in order to remove obsolete drugs and modify the clinical indications of individual Special drugs as appropriate.
Ad hoc review is also conducted in situations where an alert issued by a health authority indicates a potential impact on change in clinical practice.
Multiple Expert Panels provide professional support for the above committees. To enhance the transparency of the HA Drug Formulary and partnership with the community, HA convenes two consultation meetings with patient groups every year, one in the second quarter of each year to keep them abreast of the latest developments of the HA Drug Formulary and other in the fourth quarter to gather their major concerns, feedback and wish list on the HA Drug Formulary for annual planning consideration.
Patient groups are invited to attend meetings and submit their views and proposals to the HA for reference of relevant drug committees. Ad hoc meetings are also convened with individual patient groups to discuss specific issues of concerns where necessary.
The HA Drug Formulary is updated every three months to incorporate changes endorsed by relevant committees under established mechanisms, including addition of new drugs and indications and changes in drug category arising from funded programmes as well as biennial comprehensive and ad hoc review.
HA will keep on reviewing the HA Drug Formulary in accordance with the principle of rational use of limited public resources to benefit more patients and with reference to the latest developments in clinical research and scientific evidence.
Copyright by Hospital Authority.This final rule modernizes the Medicaid managed care regulations to reflect changes in the usage of managed care delivery systems. The final rule aligns, where feasible, many of the rules governing Medicaid managed care with those of other major sources of coverage, including coverage through.
The development of a progressive Formulary for Belau National Hospital and the Community Health Centers is a step we hope will complement the outreach programs conducted by Public Health and support the health providers in the various clinical settings. AUTHORITY / RESPONSIBILITY A.
recalled or otherwise unusable drug dispensed Formulary management Labeling of drugs Patient/family education The Pharmacy Department Director reports Pharmacy Department performance improvement activities to the hospital wide Patient Safety & Quality Improvement Council for review and recommendations.
BENEFICIARY PROTECTIONS FOR QUALIFIED PRESCRIPTION DRUG COVERAGE. Sec. D[42 U.S.C. w] Dissemination of Information.—General information.— Application of ma information.— A PDP sponsor shall disclose, in a clear, accurate, and standardized form to each enrollee with a prescription drug plan offered by the sponsor under this part at the time of enrollment and at .
Exemptions and consideration for certain drugs, devices, and biological products. The Hospital Authority (HA) provides public healthcare services to the people of Hong Kong through the Head Office and seven hospital clusters.